FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Instagram Outage Disrupts Thousands of U.S. Users 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
BRISBANE, Calif., Dec. 13, 2016 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, MD, chairman and CEO, will discuss how Priority Review Vouchers (PRVs) can continue to be effective incentives to help underserved patients during a panel at the U.S. Food and Drug Administration (FDA) / Centers for Medicare and Medicaid Services (CMS) Summit in Washington, D.C., December 14-15, 2016.
Dr. Durrant will also participate in a separate discussion on the significant needs in pediatric drug development.
“Important incentives, such as the PRV system, can support new approaches to bring treatments to many categories of underserved patients, including children,” said Dr. Durrant. “I look forward to engaging regulatory, policy and other stakeholders on how we could further collaborate and share ideas to help overlooked populations.”
Details of the panels follow:
Title: Priority Review Voucher Proliferation: Bane of FDA, Boon for Industry?
Date: Wednesday, December 14, 2016
Time: 3:30 – 4:00 p.m. EST
Participants: Krista Carver, Covington & Burling LLP; Dr. Gayatri Rao, Office of Orphan Products Development, FDA; Dr. Cameron Durrant, KaloBios Pharmaceuticals
Title: Pediatric Drug Development
Date: Thursday, December 15, 2016
Time: 11:15 a.m. – 12:00 p.m. EST
Participants: Dr. Mary Dianne Murphy, Office of Pediatric Therapeutics, FDA (retired); Dr. Stephen Yoo, REGENXBIO; Dr. Cameron Durrant, KaloBios Pharmaceuticals
For more information on the conference, please visit https://lifesciences.knect365.com/fda-cms/.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.
Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
